shockedcanadian
Diamond Member
- Aug 6, 2012
- 43,812
- 42,886
- 3,605
Even Fox News has to accept this and stop bending to their big pharma advertisers.
The future is civil liberty. Freedom will prevail only if citizens accept that people are different and must be free to choose what is best for them, getting high or not, getting drunk or not. To each their own.
www.foxnews.com
Compounds found in cannabis could provide a new roadmap for treating the world’s most common chronic liver disorder, according to a study released by the Hebrew University of Jerusalem.
The research, published in the British Journal of Pharmacology, found that cannabidiol (CBD) and cannabigerol (CBG) significantly reduced liver fat and improved metabolic health in experimental models.
CBD is the more widely studied non-intoxicating cannabinoid, while CBG is a less common "precursor" cannabinoid from which CBD is formed.
Unlike THC, the primary psychoactive component in cannabis, these compounds do not produce a "high," making them viable candidates for long-term medical treatment, the study suggests.
Metabolic dysfunction-associated steatotic liver disease (MASLD) currently affects approximately one-third of the global adult population, according to health data.
The future is civil liberty. Freedom will prevail only if citizens accept that people are different and must be free to choose what is best for them, getting high or not, getting drunk or not. To each their own.
Cannabis compounds could reverse disease affecting one-third of adults
Compounds found in cannabis could provide a new roadmap for treating the world’s most common chronic liver disorder, according to a study released by the Hebrew University of Jerusalem.
Compounds found in cannabis could provide a new roadmap for treating the world’s most common chronic liver disorder, according to a study released by the Hebrew University of Jerusalem.
The research, published in the British Journal of Pharmacology, found that cannabidiol (CBD) and cannabigerol (CBG) significantly reduced liver fat and improved metabolic health in experimental models.
CBD is the more widely studied non-intoxicating cannabinoid, while CBG is a less common "precursor" cannabinoid from which CBD is formed.
Unlike THC, the primary psychoactive component in cannabis, these compounds do not produce a "high," making them viable candidates for long-term medical treatment, the study suggests.
Metabolic dysfunction-associated steatotic liver disease (MASLD) currently affects approximately one-third of the global adult population, according to health data.


